HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Azza B El-Remessy Selected Research

Matrix Metalloproteinases (MMPs)

1/2014Role of matrix metalloproteinase activity in the neurovascular protective effects of Angiotensin antagonism.
6/2011Acute treatment with candesartan reduces early injury after permanent middle cerebral artery occlusion.
9/2009Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Azza B El-Remessy Research Topics

Disease

16Inflammation (Inflammations)
12/2021 - 01/2006
13Stroke (Strokes)
12/2021 - 05/2009
12Ischemia
01/2021 - 08/2005
10Diabetic Retinopathy (Retinopathy, Diabetic)
03/2018 - 07/2008
8Hypoxia (Hypoxemia)
08/2019 - 08/2005
7Neurodegenerative Diseases (Neurodegenerative Disease)
08/2019 - 09/2010
5Obesity
06/2020 - 02/2014
5Brain Ischemia (Cerebral Ischemia)
01/2017 - 08/2009
5Infarction (Infarctions)
01/2014 - 08/2009
4Hyperglycemia
03/2018 - 06/2012
4Ischemic Stroke
04/2015 - 08/2009
3Blindness (Hysterical Blindness)
01/2019 - 10/2009
3Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
04/2015 - 06/2011
3Hypertension (High Blood Pressure)
02/2014 - 01/2012
3Hyperoxia
01/2014 - 09/2003
3Ganglion Cysts (Ganglion)
10/2013 - 11/2003
3Neoplasms (Cancer)
10/2013 - 11/2005
3Cataract (Cataracts)
06/2012 - 06/2008
3Edema (Dropsy)
06/2011 - 09/2009
2Myocardial Infarction
03/2018 - 01/2017
2Vascular Diseases (Vascular Disease)
01/2017 - 05/2015
2Body Weight (Weight, Body)
04/2015 - 01/2014
2Pathologic Neovascularization
04/2015 - 12/2013
2Retinal Neovascularization
10/2009 - 08/2005
2Hemorrhage
09/2009 - 08/2009
1Non-alcoholic Fatty Liver Disease
12/2021
1Neuroinflammatory Diseases
01/2021
1Alzheimer Disease (Alzheimer's Disease)
01/2021
1Cognitive Dysfunction
01/2021
1Leukostasis
06/2020
1Vision Disorders (Hemeralopia)
08/2019
1Herpes Zoster
01/2019
1Alcoholic Fatty Liver
04/2018
1Fibrosis (Cirrhosis)
04/2018
1Albuminuria
03/2018
1Insulin Resistance
02/2017
1Cardiovascular Diseases (Cardiovascular Disease)
01/2017
1Chronic Limb-Threatening Ischemia
01/2017
1Disease Progression
10/2015
1Retinal Diseases
10/2015
1Weight Gain
01/2014
1Retinopathy of Prematurity (Retrolental Fibroplasia)
01/2014

Drug/Important Bio-Agent (IBA)

27Retinaldehyde (Retinal)IBA
01/2021 - 09/2003
12Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
03/2018 - 08/2005
11Proteins (Proteins, Gene)FDA Link
12/2021 - 02/2009
10ThioredoxinsIBA
12/2021 - 09/2011
7InflammasomesIBA
01/2021 - 02/2014
7Oxygen (Dioxygen)IBA
01/2018 - 09/2003
6candesartanIBA
04/2015 - 05/2009
5Nerve Growth Factor (NGF)IBA
03/2018 - 04/2014
5AntioxidantsIBA
04/2015 - 07/2008
5Peroxynitrous Acid (Peroxynitrite)IBA
06/2012 - 09/2003
4Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
06/2011 - 07/2008
3Staphylococcal Protein A (Protein A)IBA
12/2021 - 04/2015
3Nerve Growth Factor Receptors (Neurotrophin Receptors)IBA
01/2021 - 01/2017
3NLR ProteinsIBA
01/2021 - 05/2015
3Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2018 - 01/2011
3Glucose (Dextrose)FDA LinkGeneric
02/2017 - 06/2012
3Matrix Metalloproteinases (MMPs)IBA
01/2014 - 09/2009
3Caspase 3 (Caspase-3)IBA
01/2014 - 09/2003
3NADPH Oxidases (NAD(P)H oxidase)IBA
01/2012 - 08/2005
3Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
04/2009 - 09/2003
2Tight Junction ProteinsIBA
01/2019 - 01/2010
2Nerve Growth Factors (Neurotrophins)IBA
01/2017 - 10/2015
2Small Interfering RNA (siRNA)IBA
10/2016 - 04/2015
23-nitrotyrosineIBA
10/2016 - 01/2014
2Biomarkers (Surrogate Marker)IBA
01/2015 - 08/2009
2Angiotensin Receptor AntagonistsIBA
06/2014 - 01/2011
2AlbuminsIBA
07/2013 - 04/2011
2Sorbitol (Yal)FDA Link
06/2012 - 07/2010
2p38 Mitogen-Activated Protein KinasesIBA
06/2012 - 01/2006
2acetovanillone (apocynin)IBA
01/2012 - 08/2005
2Hemoglobins (Hemoglobin)IBA
06/2011 - 08/2009
2Aldehyde Reductase (Aldose Reductase)IBA
07/2010 - 06/2008
2fidarestatIBA
07/2010 - 06/2008
2Superoxides (Superoxide)IBA
08/2005 - 09/2003
1CalciumIBA
12/2021
1Reactive Oxygen Species (Oxygen Radicals)IBA
12/2021
1Nerve Growth Factor Receptor (Nerve Growth Factor Receptor, Low Affinity)IBA
01/2019
1LM11A-31IBA
01/2019
1Claudin-5IBA
01/2019
1Phosphotransferases (Kinase)IBA
01/2019
1Toll-Like Receptors (Toll-Like Receptor)IBA
04/2018
1Brain-Derived Neurotrophic Factor (BDNF)IBA
01/2018
1trkA ReceptorIBA
01/2018
1Tyrosine (L-Tyrosine)FDA Link
06/2017
1Butyric Acid (Butanoic Acid)IBA
02/2017
1salicylhydroxamic acid (SHAM)IBA
10/2016
1Actins (F Actin)IBA
10/2016
1NucleotidesIBA
05/2015
1ResveratrolIBA
04/2015
1Angiopoietin-1IBA
06/2014
1AngiotensinsIBA
01/2014
1Cyclopentolate (Cyclogyl)FDA LinkGeneric
01/2014
1Thioredoxin-Disulfide ReductaseIBA
01/2014
1Messenger RNA (mRNA)IBA
01/2014
1Cysteine (L-Cysteine)FDA Link
12/2013
1Glutathione (Reduced Glutathione)IBA
12/2013

Therapy/Procedure

6Therapeutics
04/2018 - 11/2003
1Lasers (Laser)
06/2017